April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers
May 17th 2019Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Watch
FDA Lifts Partial Hold on AIM2CERV Trial of Investigational Immunotherapy Agent in Cervical Cancer
May 15th 2019The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial, which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent.
Read More
Treatment with vaginal cuff brachytherapy plus paclitaxel and carboplatin chemotherapy was not found to be superior to pelvic radiation therapy in patients with high-intermediate and high-risk early-stage endometrial cancer, according to findings from a phase III trial recently published in the <em>Journal of Clinical Oncology</em>.
Read More
Benefit Seen With Mirvetuximab Soravtansine in Folate Receptor Alpha+ Ovarian Cancer
May 7th 2019Mirvetuximab soravtansine, an antibody-drug conjugate, led to a favorable benefit-risk profile in patients with folate receptor alpha–positive ovarian cancer according to a comprehensive analysis of the phase III FORWARD trial.
Read More
Study Finds Synergism With Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma
May 6th 2019In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD.
Read More
Study Finds Extended-Release Anagrelide Noninferior to Reference Product in ET
April 16th 2019A new phase III trial has demonstrated that a novel extended-release formulation of anagrelide (Thromboreductin) is noninferior to immediate-release anagrelide in reducing platelet counts in patients with essential thrombocythemia.
Read More
Coleman Highlights Benefit With Maintenance Rucaparib Across Ovarian Cancer Subgroups
April 8th 2019Analyses from the phase III ARIEL3 trial presented during the 2019 Society of Gynecologic Oncology Annual Meeting showed that rucaparib is safe and effective as a maintenance therapy across all subgroups of patients.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Updates to Ovarian Cancer Guidelines Emphasize Importance of Germline, Somatic Testing
April 5th 2019In an interview with <em>Targeted Oncology, </em>David O’Malley, MD, discussed the updates with bevacizumab and PARP inhibitors as a treatment and maintenance therapy option for patients with ovarian cancer and recurrent disease. He also discussed considerations for selecting the right agent for the right patient.
Read More
Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer
April 1st 2019<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.</p>
Watch
Gynecology Experts Reflect on Precision Medicine Highlights From SGO Annual Meeting
March 30th 2019Gynecologic oncology experts reflect on some of the most significant data presented during the 2019 SGO Annual Meeting, which underscored how the field is moving toward a precision medicine approach.
Read More
Phase III Trial Launches to Investigate TTFields With Paclitaxel in Recurrent Ovarian Cancer
March 26th 2019A pivotal phase III INNOVATE-3 trial investigating the efficacy of tumor-treating fields (TTFields; Optune) combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer has been initiated, according to Novocure, the company developing the device.
Read More
Durable Responses Seen With Dostarlimab in MSI-H, MSS Endometrial Tumors
March 25th 2019According to results from the ongoing phase I/II GARNET trial, dostarlimab induced an overall response rate of nearly 30% in patients with recurrent or advanced endometrial cancer. Results presented at the 2019 SGO Annual Meeting also demonstrated durable responses in both patients with microsatellite instability-high and microsatellite stable tumors.
Read More
Phase III Frontline Ovarian Cancer Trial Evaluating Avelumab Discontinued
March 20th 2019The phase III JAVELIN Ovarian PARP 100 study has been discontinued, according to Merck KGaA and Pfizer, the companies that collaborated on the trial.<sup> </sup>The ongoing trial was investigating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer.
Read More